Delivery Order SPE2DB22D3301-SPE2DB26FX3TL
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,288.86 for Envarsus XR 1 mg tablets (100-count) with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (100-count units) under a competitive, non-set-aside procurement. The contract has a ceiling value of $1,718.48 with a firm fixed-price structure and an ultimate completion date of August 27, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,288.86 to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (100 count), with an ultimate completion date of August 20, 2025. This non-set-aside, firm fixed-price delivery order was competitively awarded and represents a continuation of the contractor's pharmaceutical supply activities supporting federal medical procurement. The work will be performed at AmerisourceBergen Drug Corp's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,165.05 to AmerisourceBergen Drug Corp for 30 tablets of Envarsus XR 1 mg on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order carries no set-aside designation and represents a competitively awarded transaction under the company's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This competitively awarded, firm fixed-price delivery order is set to be completed by September 8, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a single delivery order issued under a larger contract vehicle rather than a standalone...
- The Defense Logistics Agency awarded a delivery order valued at $3,436.96 to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg on June 11, 2025, with a completion date of July 3, 2025. This firm fixed price, non-set-aside contract is being performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a small-value transaction within AmerisourceBergen's broader federal pharmaceutical supply portfolio. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,718.48. This is a firm fixed price delivery order with an ultimate completion date of August 27, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,151.68. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 16, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside contract, this award reflects AmerisourceBergen's capability to compete...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (30-count supply) with a ceiling value of $1,553.40. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and has an ultimate completion date of August 18, 2025. The delivery order is being performed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a $2,263.75 delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units. This non-set-aside, competitively awarded contract carries a firm fixed price and is scheduled for completion by November 12, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX3TLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,289.24 to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 0.75 mg, with an ultimate completion date of November 14, 2025. This firm fixed price, competitively awarded delivery order represents a single pharmaceutical procurement under the company's existing indefinite delivery contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. The award carries no set-aside designation and reflects the contractor's demonstrated capability to meet federal procurement requirements through open competition across its extensive portfolio of pharmaceutical deliveries to defense health organizations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 10/23/25 |